Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
27 Apr 2020
Long-term use of brivaracetam as an adjunctive treatment is well tolerated and effective in patients with focal seizures or primary generalized seizures, as shown in a study.
01 Apr 2019
Perampanel is safe and effective for treating refractory focal seizures in both Asian and non‐Asian populations, a study has found.
Rachel Soon, 24 Apr 2018

MIMS Pharmacist presents an overview of CoQ10's physiological role, as well as contemporary research on its pharmacology and effects.

Long-term potent antithrombotic therapy reduces atherothrombotic events after PCI

19 Mar 2020

Long-term treatment with more potent antithrombotic therapy lowers spontaneous atherothrombotic events and prevents complications related to stenting of the culprit lesion following acute coronary syndrome (ACS), suggests a recent study.

“In patients undergoing percutaneous coronary intervention [PCI] for ACS, spontaneous events predominate after 30 days, with the later-phase cardiovascular benefit of potent dual antiplatelet therapy driven largely by reducing de novo atherothrombotic ischaemic events,” the researchers said.

Of the patients included in the TRITON-TMI 38* study, which randomized participants to prasugrel or clopidogrel, 12,844 with ACS received at least one stent. Myocardial infarction (MI) and cardiovascular death were categorized as follows: procedural (related to revascularization); definite or probable stent thrombosis (ST); or spontaneous (non-ST or nonprocedural-related). Median follow-up was 14.5 months.

Of the first events that occurred within 30 days, 584 (69.0 percent) were procedural, 126 (14.9 percent) ST-related and 136 (16.1 percent) spontaneous. After 30 days, 22 (4.7 percent) events were procedural, 63 (13.5 percent) ST-related and 383 (81.8 percent) spontaneous.

Treatment with prasugrel significantly reduced the incidence of MI or cardiovascular death for ST-related (1.0 percent vs 2.1 percent; p<0.001) and spontaneous events (3.9 percent vs 4.8 percent; p=0.012), with a directionally consistent numerical reduction in procedural events (4.4 percent vs 5.1 percent; p=0.078). However, prasugrel led to more spontaneous, but not procedural, major bleeding.

“Recent emphasis on reduced duration and/or intensity of antiplatelet therapy following PCI irrespective of indication for PCI may fail to account for the substantial risk of subsequent nontarget lesion events in ACS patients,” the researchers said.

*Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis In Myocardial Infarction 38

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
27 Apr 2020
Long-term use of brivaracetam as an adjunctive treatment is well tolerated and effective in patients with focal seizures or primary generalized seizures, as shown in a study.
01 Apr 2019
Perampanel is safe and effective for treating refractory focal seizures in both Asian and non‐Asian populations, a study has found.
Rachel Soon, 24 Apr 2018

MIMS Pharmacist presents an overview of CoQ10's physiological role, as well as contemporary research on its pharmacology and effects.